Palatin Technologies’ (PTN) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Palatin Technologies (NYSEAMERICAN:PTN) in a research report released on Tuesday, Benzinga reports. HC Wainwright currently has a $17.00 price target on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Palatin Technologies’ Q1 2025 earnings at ($0.51) EPS, Q2 2025 earnings at ($0.51) EPS, Q3 2025 earnings at ($0.55) EPS, Q4 2025 earnings at ($0.51) EPS and FY2025 earnings at ($2.03) EPS.

Palatin Technologies Price Performance

NYSEAMERICAN PTN opened at $0.83 on Tuesday. The company has a market capitalization of $16.04 million, a price-to-earnings ratio of -0.33 and a beta of 1.01. Palatin Technologies has a fifty-two week low of $0.68 and a fifty-two week high of $5.65.

Palatin Technologies (NYSEAMERICAN:PTN) last released its quarterly earnings results on Tuesday, October 1st. The biopharmaceutical company reported ($0.51) earnings per share for the quarter.

Institutional Trading of Palatin Technologies

A hedge fund recently bought a new stake in Palatin Technologies stock. XTX Topco Ltd acquired a new stake in shares of Palatin Technologies, Inc. (NYSEAMERICAN:PTN) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 14,631 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. XTX Topco Ltd owned approximately 0.08% of Palatin Technologies as of its most recent SEC filing. 11.50% of the stock is currently owned by hedge funds and other institutional investors.

Palatin Technologies Company Profile

Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.